Anthera Pharmaceuticals, Inc. announced that patient recruitment is now complete for the Phase 3 RESULT clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency caused by cystic fibrosis. The RESULT study allows for more frequent and higher dose adjustments based upon clinical signs and symptoms than the previous Phase 3 SOLUTION study. As with current practice with porcine pancreatic enzyme replacement therapies, the RESULT study allows for dose increases of Sollpura on an individualized basis to achieve maximum therapeutic benefit. Sollpura has the potential to become the first non-porcine PERT, which may provide a reduction in the size and number of pills patients must consume daily due to the significantly more compact formulation of Sollpura than porcine PERTs.